NasdaqGS - Nasdaq Real Time Price USD

Rigel Pharmaceuticals, Inc. (RIGL)

16.38

-0.07

(-0.40%)

As of 11:30:45 AM EST. Market Open.

Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year

The Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) share price has had a bad week, falling 26%. But that doesn't change...

Simply Wall St. 13 days ago

RIGL
-0.40%
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being presented today by Dr. Guillermo Garcia-Manero (Poster #: 4595) at the 66th American Society of He

PR Newswire 16 days ago

RIGL
-0.40%
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety,

PR Newswire 24 days ago

RIGL
-0.40%
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%

The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

RIGL
-0.40%
Zacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive

Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive have been highlighted in this Screen of The Week article.

Zacks last month

SYF-PB

RIGL
-0.40%
SKYW
5 Relative Price Strength Options Available for Investors

RIGL, SYF, SKYW, ALNT and RSI are five stocks with explosive relative price strength.

Zacks last month

^GSPC

RIGL
-0.40%
SKYW
Exploring Three High Growth Tech Stocks in the United States

The United States market has been flat in the last week yet it is up 32% over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that align with these robust market conditions can be crucial for investors looking to capitalize on potential opportunities.

Simply Wall St. last month

RIGL
-0.40%
ADSK

TVTX
Rigel to Present at the Jefferies London Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST).

PR Newswire last month

RIGL
-0.40%
Rigel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Rigel Pharmaceuticals ( NASDAQ:RIGL ) Third Quarter 2024 Results Key Financial Results Revenue: US$55.3m (up 97% from...

Simply Wall St. last month

RIGL
-0.40%
Q3 2024 Rigel Pharmaceuticals Inc Earnings Call

Q3 2024 Rigel Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

RIGL
-0.40%
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Rigel Pharmaceuticals Inc (RIGL) reports a 44% increase in net sales and achieves positive net income, driven by robust product performance and international expansion.

GuruFocus.com last month

RIGL
-0.40%
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 6,900% and 35.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

RIGL
-0.40%
Rigel: Q3 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. AP) — Rigel Pharmaceuticals Inc. RIGL) on Thursday reported third-quarter net income of $12.4 million.

Associated Press Finance last month

RIGL
-0.40%
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2024, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP); REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML); and GAVRETO® (

PR Newswire last month

RIGL
-0.40%
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, California and virtually.

PR Newswire last month

RIGL
-0.40%
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

PR Newswire last month

RIGL
-0.40%
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO® (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA). GAVRETO is for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detecte

PR Newswire 2 months ago

RIGL
-0.40%
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction. “Under this expanded agreement, Optime Care will now mana

GlobeNewswire 2 months ago

RIGL
-0.40%
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 35,944 stock options to fifteen non-executive employees vesting over four years with a one-year cliff.

PR Newswire 2 months ago

RIGL
-0.40%
High Growth Tech Stocks in the United States to Watch

In the last week, the market has stayed flat while the Materials sector gained 3.1%, and over the past 12 months, it has risen by 32% with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks becomes crucial as they often offer significant potential for capital appreciation in a steadily advancing market.

Simply Wall St. 2 months ago

ALVO

ALVOW

FIVN

Performance Overview

Return	RIGL	S&P 500
YTD	+12.93%	+26.57%
1-Year	+16.96%	+26.98%
3-Year	-42.34%	+27.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rigel Pharmaceuticals, Inc. (RIGL)

Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%

Zacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive

5 Relative Price Strength Options Available for Investors

Exploring Three High Growth Tech Stocks in the United States

Rigel to Present at the Jefferies London Healthcare Conference

Rigel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 Rigel Pharmaceuticals Inc Earnings Call

Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates

Rigel: Q3 Earnings Snapshot

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

High Growth Tech Stocks in the United States to Watch

Performance Overview